文献速递肿瘤 PET/CT核素与放射性配体治疗

氟环洛芬 PET/CT 与盆腔多参数 MRI 在初始治疗后 PSA 升高时对盆腔前列腺癌诊断效用的比较

Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
PubMed 文献 · Clin Nucl Med · 2020-01-01

回顾性纳入 129 例初始治疗后 PSA 升高且 3 个月内完成氟环洛芬 PET/CT 与盆腔多参数 MRI 的前列腺癌患者,两种检查诊断效能无统计学显著差异,一致性 93.8%,各有局限并可互补。

要点

  • 氟环洛芬 PET/CT 与盆腔 mpMRI 诊断效能无统计学显著差异。
  • 两种检查一致性 93.8%(121/129)。
  • 不一致病例中 PET/CT 与 mpMRI 各有优势与局限,可互补。

核心结论

  • 单中心研究显示,初始治疗后 PSA 升高时,氟环洛芬 PET/CT 检测盆腔复发/转移性前列腺癌的诊断效能与盆腔 mpMRI 相似。
  • 氟环洛芬 PET/CT 与 mpMRI 在不同临床情形下意义不同,各有局限与陷阱,但可互补。

研究设计与样本

  • 回顾性研究,纳入 2017 年 10 月至 2018 年 10 月在本中心接受氟环洛芬 PET 与盆腔 mpMRI 的前列腺癌患者。
  • 纳入标准为氟环洛芬 PET/CT 与 mpMRI 间隔在 3 个月内。
  • 排除标准为合并其他同时存在的癌症,或两次影像检查之间 PSA 差异超过 2 倍且绝对差值超过 1 ng/mL。
  • 共纳入 129 例患者、129 对配对检查,结果由病理或其他影像技术验证,临床随访至少 10 个月。

主要发现

  • 氟环洛芬 PET/CT 与盆腔 MRI 高度一致(121/129,93.8%)。
  • 氟环洛芬 PET/CT 的敏感性、特异性、阳性预测值、阴性预测值分别为 96.6%、94.3%、93.4%、97%。
  • mpMRI 的敏感性、特异性、阳性预测值、阴性预测值分别为 91.5%、95.7%、94.7%、93%。
  • 两种影像检查的诊断效能无统计学显著差异。
  • 8/129 例不一致病例中,氟环洛芬 PET/CT 在 mpMRI 因基准标记物顺磁性伪影而模棱两可时提供明确诊断并检出正常大小区域淋巴结,mpMRI 检出亚厘米尿道周围复发并澄清氟环洛芬 PET/CT 未识别的生理性尿液伪影。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称本研究为单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate the imaging diagnostic performance of F-fluciclovine PET/CT and pelvic multiparametric MRI (mpMRI) for prostate cancer in the setting of rising PSA after initial treatment, with a focus on detection of recurrent and metastatic prostate cancer in the pelvis. METHODS: Patients with prostate cancer who had fluciclovine PET and pelvic mpMRI between October 2017 and October 2018 in our center were retrospectively reviewed. Patients were included if they had fluciclovine PET/CT and mpMRI within a 3-month interval. Patients were excluded if they had separate concurrent cancer or if the PSA were more than 2-fold difference with an absolute difference more than 1 ng/mL between the 2 image studies. For each eligible patient, we compared all abnormal lesions identified on either scan. The findings were verified by pathology or other imaging techniques within minimal 10-month clinical follow-up. RESULTS: A total of 129 patients with 129 paired tests were included in this study. Fluciclovine PET/CT and pelvic MRI had a high degree of concordance (121/129, 93.8%). The sensitivity, specificity, positive predictive value, and negative predictive value for fluciclovine PET/CT and mpMRI were 96.6%, 94.3%, 93.4%, and 97%, and 91.5%, 95.7%, 94.7%, and 93%, respectively. There were no statistical significant differences in diagnostic performance between the 2 imaging tests. Among the 8/129 discordant cases, although fluciclovine PET/CT provided definitive diagnosis when mpMRI was equivocal due to paramagnetic artifacts from fiducial markers and detected normal-sized regional lymph nodes, mpMRI detected subcentimeter periurethral recurrence and clarified physiological urinary artifacts that was not appreciated on fluciclovine PET/CT. CONCLUSIONS: Our single-center study demonstrated that fluciclovine PET/CT has similar diagnostic performance with pelvic mpMRI in detecting recurrent/metastatic prostate disease in the pelvis in the setting of rising PSA after initial treatment. Moreover, fluciclovine PET/CT and mpMRI have different implications in different clinical scenario; each test has its own limitation and pitfalls, but can be complementary to each other.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chen B, Bathala TK, Xu G, et al. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clin Nucl Med. 2020. PMID: 31977495. doi:10.1097/RLU.0000000000002963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。